Art. -Nr.: HY-B0686

Eptifibatide

9 Cited Publications

Kundenbewertung

Based on 9 publication(s) in Google Scholar

Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.79%
CAS. Nr.: 188627-80-7
Formel: C₃₅H₄₉N₁₁O₉S₂
Molecular Weight:831.96

Speicherung:

Sealed storage, away from moisture and light.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Eptifibatide Chemical Structure

CAS. Nr.: 188627-80-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- Clinical Trial
Chemical Information
Publications (9)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity^[1].

Alle Integrin Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
Platelet	IC₅₀	0.012 μM Compound: Eptifibatide	Antiplatelet activity in platelet (unknown origin) assessed as inhibition of platelet aggregation Antiplatelet activity in platelet (unknown origin) assessed as inhibition of platelet aggregation	[PMID: 24461295]

In Vitro

Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 188627-80-7
Appearance Solid
Molecular Weight 831.96
Formel C₃₅H₄₉N₁₁O₉S₂
Color White to off-white
Sequence

MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH2
Sequence Shortening

MPA-HAR-GDWPC-NH2
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Sealed storage, away from moisture and light

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (9)

All Bio/Physico-chemical AssayHistological Imaging/StainingIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Nat Commun

Protein disulfide isomerase cleaves allosteric disulfides in histidine-rich glycoprotein to regulate thrombosis. [Abstract]

2024 Apr 11;15(1):3129. PMID: 38605050

Eptifibatide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Apr 11;15(1):3129. [Abstract]

The median fluorescence intensity of HRG and platelets were calculated and plotted over time from mice treated or untreated with Eptifibatide (10 μg/g body weight, repeated every 15-20 min).

Eptifibatide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Apr 11;15(1):3129. [Abstract]

The scatter plot of pixel intensities of green (HRG) and red (CD31) fluorescence in ROI1 and ROI2 as indicated were presented. The Pearson's correlation coefficients (r) for pixels with intensity above the threshold (indicated by the dashed lines) in the thrombus (ROI2) and in the area without the thrombus (ROI1-ROI2) were inserted. Veh vehicle, Epti eptifibatide.

Eptifibatide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Apr 11;15(1):3129. [Abstract]

When mice were treated with eptifibatide, an integrin α_IIbβ3 antagonist that eliminated platelet deposition and thus platelet-derived Zn²⁺, HRG accumulation at the site of vessel injury was significantly reduced by 58.3%.
Pharmacol Res

Anti-thrombotic effects mediated by dihydromyricetin involve both platelet inhibition and endothelial protection. [Abstract]

2021 May:167:105540. PMID: 33711433
Life Sci

Mechanistic insights into PPARγ's role in suppressing collagen-driven platelet activation. [Abstract]

2026 Jan 15:385:124138. PMID: 41354414
Int J Mol Sci

A Combined Activity of Thrombin and P-Selectin Is Essential for Platelet Activation by Pancreatic Cancer Cells. [Abstract]

2021 Mar 24;22(7):3323. PMID: 33805059
Am J Respir Cell Mol Biol

GP IIb/IIIa-ICAM-1 Mediated Platelet-Endothelial Adhesion Exacerbates Pulmonary Hypertension. [Abstract]

2025 Feb 28. PMID: 40019848
Platelets

Antiplatelet effects of the CEACAM1-derived peptide QDTT. [Abstract]

2024 Dec;35(1):2308635. PMID: 38345065
J Thromb Thrombolysis

The inhibitory effect of antiplatelet drugs on spontaneous platelet aggregation on glass surfaces: an analysis based on microscopic three-dimensional topography. [Abstract]

2025 Sep 9. PMID: 40924280
University of Bonn

2023 May 31.
Ghent University

2018 May.

Eptifibatide purchased from MedChemExpress. Usage Cited in: Ghent University. 2018 May.

Concentration eptifibatide in function of buffer volume eluted from the column.

Eptifibatide purchased from MedChemExpress. Usage Cited in: Ghent University. 2018 May.

Calibration curve eptifibatide (0.25 mg/mL-0,00012207 mg/mL).

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 200 mg/mL (240.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 50 mg/mL (60.10 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2020 mL

6.0099 mL

12.0198 mL

5 mM

0.2404 mL

1.2020 mL

2.4040 mL

10 mM

0.1202 mL

0.6010 mL

1.2020 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (2.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (2.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (2.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (120.20 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Gilchrist IC, et al. Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide. Clin Pharmacokinet. 2003;42(8):703-20. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	1.2020 mL	6.0099 mL	12.0198 mL	30.0495 mL
	5 mM	0.2404 mL	1.2020 mL	2.4040 mL	6.0099 mL
	10 mM	0.1202 mL	0.6010 mL	1.2020 mL	3.0050 mL
	15 mM	0.0801 mL	0.4007 mL	0.8013 mL	2.0033 mL
	20 mM	0.0601 mL	0.3005 mL	0.6010 mL	1.5025 mL
	25 mM	0.0481 mL	0.2404 mL	0.4808 mL	1.2020 mL
	30 mM	0.0401 mL	0.2003 mL	0.4007 mL	1.0017 mL
	40 mM	0.0300 mL	0.1502 mL	0.3005 mL	0.7512 mL
	50 mM	0.0240 mL	0.1202 mL	0.2404 mL	0.6010 mL
	60 mM	0.0200 mL	0.1002 mL	0.2003 mL	0.5008 mL
DMSO	80 mM	0.0150 mL	0.0751 mL	0.1502 mL	0.3756 mL
DMSO	100 mM	0.0120 mL	0.0601 mL	0.1202 mL	0.3005 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Eptifibatide

9 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Eptifibatide

Macrocyclic Compound Library

Peptide Library

Cyclic Peptide Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Publications Citing Use of MedChemExpress (MCE) Eptifibatide

Alle Integrin Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (9)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Eptifibatide

Macrocyclic Compound Library

Peptide Library

Cyclic Peptide Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Publications Citing Use of MedChemExpress (MCE) Eptifibatide

Alle Integrin Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (9)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Eptifibatide Related Classifications

HY-B0686 Related Classifications